Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Company Outlines Roadmap to Develop Successful Therapies for Neurodegenerative Diseases Based on its Broad Anti-Tau Clinical Pipeline
HOOKIPA Pharma Inc. reported recent clinical progress highlights and financial results for the second quarter ended June 30, 2019.
Adrenomed AG, the vascular integrity company, announced its participation at four upcoming conferences in Europe.
LGC announced the acquisition of a majority stake in Toronto Research Chemicals, a leading manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a highly diversified global customer base across the pharmaceutical, applied and research sectors.
Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 (“Q3" & “YTD”), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals.
Assertio Therapeutics, Inc. announced it has entered into separate, privately negotiated exchange agreements with a limited number of holders of Assertio’s currently outstanding 2.50% Convertible Notes due 2021.
HALIX announced that they have met their major milestone with the interim delivery of their new 6,700 m2 cGMP facility in Leiden Bio Science Park.
Sareum Holdings PLC, the specialist small molecule drug development business notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has announced its financial and operational results for the second quarter 2019 ended 30 June 2019.
Esperion provided bempedoic acid franchise development program updates and financial results for the second quarter ended June 30, 2019.
Neos Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2019 and provided a business update.